Huntington’s Disease Treatment Market Size Reaches $0.92 Billion In 2026: What Is Driving Growth?
Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Huntington’s Disease Treatment Market Size, Value And Growth Trajectory Through 2030
The huntington’s disease treatment market size has experienced rapid growth in recent years. It is anticipated to expand from $0.82 billion in 2025 to $0.92 billion in 2026, at a compound annual growth rate (CAGR) of 12.6%. This historical growth can be attributed to several factors including limited treatment options for neurodegenerative disorders, an increasing diagnosis of genetic neurological diseases, early reliance on symptomatic management, the expansion of neurology specialty care, and growth in hospital-based neurological treatments.
The huntington’s disease treatment market is projected for significant expansion in the coming years. It is anticipated to reach $1.48 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.6%. This expansion throughout the forecast period can be attributed to several factors, including breakthroughs in gene therapy technologies, increased investment in rare disease research, a rise in orphan drug designations, the growing acceptance of precision medicine, and a broader pipeline of disease-modifying therapies. Key trends expected during this period involve an increasing focus on disease-modifying treatments, wider adoption of gene and RNA-based therapies, the expansion of combination therapy strategies, a heightened emphasis on developing symptom-specific drugs, and a surge in clinical trial activities for rare neurological conditions.
Get A Free Sample Report With In-Depth Market Insights:
Huntington’s Disease Treatment Market Growth Drivers: What’s Behind The Acceleration?
The rising prevalence of gene therapies is anticipated to significantly advance the Huntington’s disease treatment market in the coming years. Gene therapies are therapeutic approaches designed to modify or substitute impaired genes, aiming to alleviate or avert diseases at their fundamental genetic origin. Their expansion is fueled by advancements in precision medicine, allowing for direct targeting of genetic anomalies and yielding superior results compared to conventional remedies. For Huntington’s disease, gene therapies function by silencing the malfunctioning HTT gene, which is responsible for producing detrimental proteins, thereby safeguarding nerve cells from damage. This methodology contributes to decelerating disease progression, preserving brain function, and offers prospects for sustained management. As an illustration, data from July 2023, compiled by the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, indicated that 247 gene therapies were in phase II at the close of Q1 2023. This figure subsequently increased by 5%, reaching 260 by the conclusion of Q2. Consequently, the expanding landscape of gene therapies is serving as a key impetus for the expansion of the Huntington’s disease treatment market.
Huntington’s Disease Treatment Market Breakdown By Product Type And Application
The huntington’s disease treatment market covered in this report is segmented –
1) By Treatment: Symptomatic Treatment, Disease-Modifying Therapies
2) By Administration Type: Oral, Intravenous, Subcutaneous, Topical
3) By Therapeutic: Genetic Disorders, Neurological Disorders, Psychiatric Disorders
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Clinics, Homecare Settings, Research Centers
Subsegments:
1) By Symptomatic Treatment: Antidepressants, Antipsychotics, Mood Stabilizers, Chorea Medications, Cognitive Enhancers
2) By Disease-Modifying Therapies: Gene Therapy, Neuroprotective Agents, RNA-Based Therapies, Stem Cell Therapy, Protein-Targeting Therapies
Huntington’s Disease Treatment Market Trends: What’s Defining The Industry’s Next Phase?
Leading companies within the Huntington’s disease treatment market are concentrating on developing innovative therapies, including selective vesicular monoamine transporter 2 (VMAT2) inhibitor capsules, with the goal of potentially enhancing patient quality of life and slowing disease progression. Selective VMAT2 inhibitor capsules are medicines that work by blocking vesicular monoamine transporter 2, a protein responsible for packaging neurotransmitters for release in the brain. These drugs contribute to reducing neurotransmitter release, which helps in managing involuntary movements and related symptoms. For example, in August 2023, Neurocrine Biosciences, Inc., a US-based biotech company, secured approval from the U.S. Food and Drug Administration (FDA) for its Ingrezza (valbenazine) capsules, intended for treating chorea associated with Huntington’s disease (HD) in adults. These capsules represent a once-daily oral VMAT2 inhibitor that functions by diminishing excessive dopamine signaling in the brain to help regulate involuntary movements. The medication is provided in various capsule strengths and can be consumed either with or without food, presenting a flexible dosing solution for patients.
Huntington’s Disease Treatment Market Company Landscape And Competitive Strategy
Major companies operating in the huntington’s disease treatment market are F. Hoffmann-La Roche Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Neurocrine Biosciences Inc., Wave Life Sciences Ltd., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., uniQure N.V., Prilenia Therapeutics B.V., Sage Therapeutics Inc., Annexon Inc., Alnylam Pharmaceuticals Inc., Sun Pharmaceutical Industries Inc., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Hikma Pharmaceuticals plc, Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd., AbbVie Inc.
View The Full Huntington’s Disease Treatment Market Report:
Huntington’s Disease Treatment Market Geographic Distribution And Regional Opportunities
North America was the largest region in the Huntington’s disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the huntington’s disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
